The Association Between Perioperative Denosumab and Local Recurrence After Surgical Management of Giant Cell Tumors: A Meta-Analysis.
메타분석
2/5 보강
TL;DR
In this meta-analysis, patients receiving denosumab only preoperatively did not have a significantly increased rate of LR compared with controls, and patients receiving denosumab only preoperatively did not have a significantly increased rate of LR compared with controls.
OpenAlex 토픽 ·
Bone Tumor Diagnosis and Treatments
Musculoskeletal synovial abnormalities and treatments
Sarcoma Diagnosis and Treatment
In this meta-analysis, patients receiving denosumab only preoperatively did not have a significantly increased rate of LR compared with controls, and patients receiving denosumab only preoperatively d
- p-value p = 0.03
- p-value p < 0.001
- 추적기간 40 months
- 연구 설계 meta-analysis
APA
Mohammad Daher, Tarek Nahle, et al. (2026). The Association Between Perioperative Denosumab and Local Recurrence After Surgical Management of Giant Cell Tumors: A Meta-Analysis.. The Journal of bone and joint surgery. American volume, 108(8), 564-571. https://doi.org/10.2106/JBJS.25.01058
MLA
Mohammad Daher, et al.. "The Association Between Perioperative Denosumab and Local Recurrence After Surgical Management of Giant Cell Tumors: A Meta-Analysis.." The Journal of bone and joint surgery. American volume, vol. 108, no. 8, 2026, pp. 564-571.
PMID
41662446 ↗
Abstract 한글 요약
[BACKGROUND] Several studies have assessed the impact of perioperative denosumab on local recurrence (LR) after surgical management of giant cell tumor (GCT), with conflicting results. This meta-analysis evaluates the association between LR in patients undergoing surgical management of GCT and perioperative denosumab, accounting for the type of surgery, number of denosumab doses, and timing of denosumab administration.
[METHODS] Following the PRISMA guidelines, PubMed, Cochrane, and Google Scholar were searched until December 5, 2024. The extracted outcomes consisted of LR and denosumab-related complications.
[RESULTS] Sixteen studies from 15 cohorts were included in the meta-analysis. The number of patients totaled 1,551: 310 (20%) in the denosumab group (mean age, 32 years; mean follow-up, 40 months) and 1,241 (80%) in the control group (mean age, 32 years; mean follow-up, 62 months). Patients in the denosumab group had a significantly higher rate of LR compared with patients in the control group (odds ratio = 1.82; p = 0.03), and this remained true even when looking at studies using curettage as the only surgical management (odds ratio = 2.75; p < 0.001). In a subgroup analysis by the timing of denosumab administration, a significantly higher rate of LR was only found among patients receiving denosumab both preoperatively and postoperatively (odds ratio for recurrence relative to control = 5.57; p < 0.001). Overall, the reported incidence of denosumab-related complications was 6.5%.
[CONCLUSIONS] In this meta-analysis, patients receiving denosumab only preoperatively did not have a significantly increased rate of LR compared with controls. Increased recurrence was observed primarily in patients being treated with both preoperative and postoperative denosumab.
[LEVEL OF EVIDENCE] Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
[METHODS] Following the PRISMA guidelines, PubMed, Cochrane, and Google Scholar were searched until December 5, 2024. The extracted outcomes consisted of LR and denosumab-related complications.
[RESULTS] Sixteen studies from 15 cohorts were included in the meta-analysis. The number of patients totaled 1,551: 310 (20%) in the denosumab group (mean age, 32 years; mean follow-up, 40 months) and 1,241 (80%) in the control group (mean age, 32 years; mean follow-up, 62 months). Patients in the denosumab group had a significantly higher rate of LR compared with patients in the control group (odds ratio = 1.82; p = 0.03), and this remained true even when looking at studies using curettage as the only surgical management (odds ratio = 2.75; p < 0.001). In a subgroup analysis by the timing of denosumab administration, a significantly higher rate of LR was only found among patients receiving denosumab both preoperatively and postoperatively (odds ratio for recurrence relative to control = 5.57; p < 0.001). Overall, the reported incidence of denosumab-related complications was 6.5%.
[CONCLUSIONS] In this meta-analysis, patients receiving denosumab only preoperatively did not have a significantly increased rate of LR compared with controls. Increased recurrence was observed primarily in patients being treated with both preoperative and postoperative denosumab.
[LEVEL OF EVIDENCE] Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.